Impact of Von Willebrand Factor-platelet Aggregates in Patients With Type 2B Disease (Von2B)
Primary Purpose
Von Willebrand Disease, Type 2B
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
3T (Tesla) Magnetic Resonance Imaging (MRI)
Sponsored by
About this trial
This is an interventional basic science trial for Von Willebrand Disease, Type 2B focused on measuring VWF, Type 2B von willebrand disease
Eligibility Criteria
Inclusion Criteria:
- patients with type 2B disease
- neurological signs
- signature of inform consent
Exclusion Criteria:
- contraindication for MRI
- Pregnant women
- other hemorrhagic disease
Sites / Locations
- University HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Von Willebrand Disease Type 2B patient with neurological symptoms
Arm Description
evaluation of patients using 3T (Tesla) Magnetic Resonance Imaging (MRI) and series of neuropsychological tests that cover virtually all cognitive domains.
Outcomes
Primary Outcome Measures
Rate of cerebral lesions in patients with type 2B disease
Analysis of MRI sequences and % of patients with cerebral lesions
Secondary Outcome Measures
Global cognitive function evaluation
Mini Mental State Examination (MMSE) will be used
Verbal memory function evaluation
Rey Auditory Verbal Learning Test (RAVLT) will be used
Visuospatial memory evaluation
Rey's Complex Figure Test (RCFT) will be used
Speed of mental processes evaluation
Stroop test will be used
Attention evaluation
Verbal series attention test (VSAT) will be used
Subjective cognitive failures evaluation
Cognitive failures questionnaire (CFQ) will be used
Full Information
NCT ID
NCT05015244
First Posted
July 20, 2021
Last Updated
August 23, 2022
Sponsor
University Hospital, Caen
1. Study Identification
Unique Protocol Identification Number
NCT05015244
Brief Title
Impact of Von Willebrand Factor-platelet Aggregates in Patients With Type 2B Disease
Acronym
Von2B
Official Title
Impact of Von Willebrand Factor-platelet Aggregates in Patients With Type 2B Disease
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2019 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Caen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The working hypothesis is that patients with Von Willebrand Disease-type 2B may have neurological symptoms due to the chronic formation of platelets/Von Willebrand Factor aggregates. Interestingly, several patients present nonspecific neurological symptoms (nystagmus, headaches, memory disorder, …) which may be associated with cerebral microangiopathy and chronic microvessel inflammation secondary to Von Willebrand Disease-type 2B due to chronic exposure to Von Willebrand Factor-platelets complexes.
Detailed Description
Investigator will use an extensive series of neuropsychological tests that cover virtually all cognitive domains. A measurement of global cognitive function will be assessed by the Mini Mental State Examination (MMSE). The verbal memory function will be assessed by the Rey Auditory Verbal Learning Test (RAVLT). Visuospatial memory will be administered by the Rey's Complex Figure Test (RCFT). To evaluate speed of mental processes, Stroop test (three subtasks), the Paper and Pencil Memory Scanning Task (four subtasks), the Symbol-Digit Substitution Task will be used. To evaluate attention, the verbal series attention test (VSAT) will be used. To register subjective cognitive failures investigator will administer the Cognitive failures questionnaire (CFQ). The neurological evaluation will be completed with 3T (Tesla) Magnetic Resonance Imaging (MRI) with different MRI sequences including T1 3D SPACE, FLAIR 3D , 3D SWI (Susceptibility weighted imaging) and 2D EPI (Echo Planar Imaging) to address the presence of cerebral small vessel disease. The presence of each of the four MRI markers for cerebral small vessel disease (white matter hyperintensities, lacunes, cerebral microbleeds and perivascular spaces will be addressed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Von Willebrand Disease, Type 2B
Keywords
VWF, Type 2B von willebrand disease
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Von Willebrand Disease Type 2B patient with neurological symptoms
Arm Type
Experimental
Arm Description
evaluation of patients using 3T (Tesla) Magnetic Resonance Imaging (MRI) and series of neuropsychological tests that cover virtually all cognitive domains.
Intervention Type
Procedure
Intervention Name(s)
3T (Tesla) Magnetic Resonance Imaging (MRI)
Other Intervention Name(s)
Series of neuropsychological tests that cover virtually all cognitive domains
Intervention Description
Neurological evaluation using MRI and neuropsychological tests
Primary Outcome Measure Information:
Title
Rate of cerebral lesions in patients with type 2B disease
Description
Analysis of MRI sequences and % of patients with cerebral lesions
Time Frame
at the inclusion
Secondary Outcome Measure Information:
Title
Global cognitive function evaluation
Description
Mini Mental State Examination (MMSE) will be used
Time Frame
at the inclusion
Title
Verbal memory function evaluation
Description
Rey Auditory Verbal Learning Test (RAVLT) will be used
Time Frame
at the inclusion
Title
Visuospatial memory evaluation
Description
Rey's Complex Figure Test (RCFT) will be used
Time Frame
at the inclusion
Title
Speed of mental processes evaluation
Description
Stroop test will be used
Time Frame
at the inclusion
Title
Attention evaluation
Description
Verbal series attention test (VSAT) will be used
Time Frame
at the inclusion
Title
Subjective cognitive failures evaluation
Description
Cognitive failures questionnaire (CFQ) will be used
Time Frame
at the inclusion
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients with type 2B disease
neurological signs
signature of inform consent
Exclusion Criteria:
contraindication for MRI
Pregnant women
other hemorrhagic disease
Facility Information:
Facility Name
University Hospital
City
Caen
State/Province
Calvados
ZIP/Postal Code
14000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frederic VARNIER
Phone
0231063106
Ext
+33
Email
directiongenerale@chu-caen.fr
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Impact of Von Willebrand Factor-platelet Aggregates in Patients With Type 2B Disease
We'll reach out to this number within 24 hrs